Keyphrases
Tolvaptan
100%
Congestive Heart Failure
100%
Kampo
100%
Short-term Effects
100%
Goreisan
100%
Medical Therapy
100%
Urine Volume
83%
B-type Natriuretic Peptide
33%
Aquaporin-2 (AQP2)
33%
Confidence Interval
16%
Japan
16%
Congestion
16%
Acute Decompensated Heart Failure
16%
Body Fluids
16%
Odds Ratio
16%
Tokyo
16%
Cyclic Adenosine Monophosphate (cAMP)
16%
Regulatory Effect
16%
Urine Osmolality
16%
Biological Mechanisms
16%
Baseline Factors
16%
Collecting Duct
16%
Aquaresis
16%
Body Fluid Balance
16%
Diuretic Therapy
16%
Conventional Diuretics
16%
Urinary Biomarkers
16%
Medicine and Dentistry
Patient with Congestive Heart Failure
100%
Tolvaptan
100%
Combination Therapy
100%
Kampo
100%
Brain Natriuretic Peptide
66%
Congestive Heart Failure
66%
Aquaporin 2
66%
Biological Marker
33%
Body Fluid
33%
Cyclic AMP
33%
Collecting Duct
33%
Diuretic Therapy
33%
Water Balance
33%
Odds Ratio
33%
Pharmacology, Toxicology and Pharmaceutical Science
Kampo Medicine (Drug)
100%
Combination Therapy
100%
Tolvaptan
100%
Congestive Heart Failure
100%
Brain Natriuretic Peptide
40%
Aquaporin 2
40%
Biological Marker
20%
Cyclic AMP
20%
Diuretic Therapy
20%
Biochemistry, Genetics and Molecular Biology
Tolvaptan
100%
Aquaporin 2
66%
Blood Plasma
66%
Brain Natriuretic Peptide
66%
Cyclic Adenosine Monophosphate
33%
Liquid
33%
Urine Osmolality
33%
Body Water
33%